Objectives. To describe short-term clinical and echocardiography outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). To explore patient selection criteria for treatment with TAVI.
INTRODUCTION
Aortic stenosis (AS) is the most common valvular disease found in developed countries and its prevalence increases with age (1) . The survival with medical treatment of symptomatic aortic stenosis is poor and surgical aortic valve replacement (SAVR) is advised in patients with symptomatic aortic stenosis, according to current guidelines (1) (2) (3) . Reports on SAVR show an excellent short and long term outcome with current patient selection (4) (5) (6) . However, a variety of factors, such as increasing age, poor left ventricular function, renal dysfunction, anemia, low body mass index, pulmonary hypertension and cerebrovascular disease have been identified to increase surgical mortality and morbidity (4, (6) (7) (8) . Some patients also present with technical difficulties like heavily calcified ascending aorta, patent coronary grafts after previous cardiac surgery or sequelae of chest radiation that make SAVR challenging (9) .
Since the first percutaneous transcatheter aortic valve implantation (TAVI) procedure in human in 2002 described by Cribier et al. (10) , TAVI techniques have developed to provide an alternative approach in patients for whom SAVR infers an unacceptable high risk (9) .
Because TAVI is a new therapy its procedural outcome needs to be evaluated in relation to SAVR (11) . To optimize the benefit of TAVI, objective patient selection criteria for TAVI have to be established.
The aim of this study was to describe short-term clinical outcomes, echocardiographic results and 6-months mortality in two groups of matched patients undergoing TAVI and SAVR, respectively. In addition, we wanted to analyze factors influencing the choice of TAVI as treatment for aortic stenosis.
MATERIAL AND METHODS

Study design
At the introduction of TAVI at Linköping University Hospital a prospective, descriptive study, including TAVI and SAVR patients, was designed to evaluate the patients undergoing TAVI in relation to a matched group of patients undergoing SAVR. The study was approved by the Regional Ethical Review Board in Linköping, Sweden and informed, written consent was obtained.
Patients
At our center, serving a population of approximately one million, patients with symptomatic aortic stenosis accepted for SAVR or TAVI were continuously recruited to the study population. A team of cardiologists and cardiac surgeons reviewed and accepted patients for SAVR or for TAVI. TAVI was primly considered in case of high surgical risk in terms of predicted mortality with logistic European System for Cardiac Operative Risk Evaluation (logEuroSCORE) > 15% (12) . Patients with logEuroSCORE < 15% were not excluded from treatment with TAVI in the presence of factors which made treatment with TAVI preferable in the opinion of the decision board. Table 1 .
Only patients with calcific AS and a hinge-point diameter within the range of 18 to 25 mm were accepted for TAVI. The transfemoral access route was preferred. In case computer tomography verified severe iliofemoral arterial disease or <7-8 mm diameter of the common femoral artery (depending on the TAVI valve size), the transapical approach was chosen.
During the study period, a total of 62 patients underwent TAVI and 45 agreed to take part in the study. Transfemoral approach was chosen in 29 patients and transapical in 16 patients. Table 2 . Inc, Irvine, Calif) was used for implantation (13, 14) . Before implantation the stent valve was mechanically crimped onto a balloon catheter. During transfemoral procedures, vascular access was obtained with percutaneous puncture of the femoral artery. Through the opposite femoral artery a pigtail catheter was placed in the aortic root. On the same side the femoral vein was punctured and a 6 Fr introducer was inserted to secure venous access in case of intraprocedural haemodynamic instability requiring extra cardiopulmonary bypass (CPB) support. Balloon valvuloplasty, followed by implantation of the valve during rapid right ventricular burst pacing, was performed according to standard TAVI procedure routine. TEE and fluoroscopy in preselected views guided by transthoracic echocardiography according to an in-house developed procedure reduced the need for angiography at this step (15) . Femoral access point was in the majority of cases closed with percutaneous sutures (Perclose® ProGlide™, Abbot Vascular, Calif), but in some cases surgical cut down was needed. The prosthetic valve function was evaluated with TEE before patient was taken to the intensive care unit During transapical procedures a minimal left-sided thoracotomy was performed, the pericardium opened, purse string sutures applied, and an apical needle puncture was performed. After valve deployment the puncture site of the left ventricle and the thoracotomy were surgically closed.
Procedures
SAVR
The patients underwent surgery using standard techniques with cardiopulmonary bypass (CPB) and aortic cross clamping. Ringer's acetate and mannitol was used for priming the extracorporeal circuit. Moderate hemodilution (hematocrit 20-25%) and mild hypothermia (33-36 C) were usually employed. Antegrade (18%) or combined ante-and retrograde (82%) delivery of a cold blood cardioplegia were used for myocardial protection. Weaning from CPB was started at a rectal temperature of 35-36 C. Heparin was neutralized with protamine chloride.
Statistical analysis
Categorical variables are presented as numbers and frequencies and continuous variables as means ± standard deviation. Nonparametric statistical calculations were performed on all variables. Fischer's exact test was used for comparison of categorical variables and MannWhitney-U test was used for continuous variables. A value of p<0.05 was considered statistically significant. STATISTICA 9.0 (StatSoft Inc., Tulsa, Okla) was used for all statistical analyses. 
RESULTS
TAVI
Procedural outcome
In the TAVI group 12 patients (27%) had periprocedural access site complications. Out of these, 8 (18%) patients had femoral artery bleeding. Two patients (4%) had bleeding from the apical portion of the heart. Both died from AMI and respiratory/cardiac failure at day 2 and 15, respectively. One patient had iliac dissection with subsequent vascular repair and died after 106 days due to leg ischemia and exacerbations of chronic obstructive pulmonary disease. In one patient the femoral artery was occluded and required surgery, development of acute compartment syndrome and fasciotomy followed.
Severe circulatory failure after rapid pacing occurred in 3 (7%) patients. Heart compressions were given in two cases for 5 and 22 minutes respectively and the latter was followed by 35 minutes of CPB support. Both patients became circulatory stable but the one needing CPB support died at day 6 due to multi organ failure. In the third patient circulatory failure was pharmacologically treated. Acute intraoperative hemopericardium of hemodynamic significance occurred in one patient and was successfully treated with percutaneous pericardial drainage.
Postoperative pericardial tamponade, compromising cardiac function occurred in 3 (7%) patients and they were treated with pericardial drainage. One of these died from multiorgan failure due to the combination of liver bleeding, aspiration pneumonia and AMI.
In the group of patients undergoing SAVR, 4 (9%) patients became circulatory unstable after disconnecting CPB requiring measurements such as inotropic treatment and in one case treatment with intra-aortic balloon pump. In one of the circulatory unstable patients, right coronary artery (RCA) dysfunction called for coronary grafting which resulted in recovery of the right ventricular function.
Clinical outcome
There were no significant differences in mortality, periprocedural stroke, AMI or postoperative renal function between the TAVI and SAVR groups. Postoperative onset of atrial fibrillation or flutter was more common after SAVR than after TAVI (60% vs. 18%, p<0.001). Erythrocytes and thrombocytes were transfused to less patients in the TAVI group (53% vs. 78%, p=0.026) and (7% vs. 27% p=0.021) respectively. Time on ventilator was longer in the TAVI group compared to the SAVR group (15±58 h vs. 12±30 h, p=0.002).
More details on clinical outcome are given in Table 3 .
During the study period, there was a tendency in the TAVI group to a decrease in procedure time and ICU stay and a significant decrease in time on ventilator. The need of erythrocyte and plasma transfusion also decreased significantly. Table 4 . 
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DISCUSSION
The results of our study confirm the findings in previous studies that TAVI provides good short-term clinical outcomes in patients with high risk for mortality and morbidity after cardiac surgery (3, 5, 16, 17) . These patients also present with excellent good post procedural hemodynamic results.
The two groups of patients in our study are not entirely comparable. The TAVI procedure was a new interventional technique at our center and it was predominantly considered as an alternative for patients with a high surgical risk. Therefore it was not an option to conduct a randomized study. The comparison in clinical outcomes between the TAVI and SAVR groups must be interpreted in the light of differences in baseline characteristic. However, good comparisons regarding post procedural hemodynamics could be made. This study shows low 30-day mortality in both groups regarding the predicted logEuroSCORE. Large surgical series report a 3% to 10% operative mortality for isolated SAVR in patients over 70 years of age (18) (19) (20) . Furthermore, there were no differences in 30-day mortality between the groups in spite of the doubled logEuroSCORE in the TAVI group.
The TAVI group had a shorter procedure time, lower incidence of postoperative atrial fibrillation and fewer patients needed erythrocyte transfusion. Still, the need of erythrocyte and plasma transfusion was higher than expected in the TAVI group. This may be related to femoral artery and apical cardiac bleeding complications and it were more than halved in the last 20 compared to the first 25 TAVI patients. Periprocedural access site complications, including minor complications, seem to be high among TAVI patients but only one patient required surgery. None of the mortalities within 30-day from surgery were directly associated to access site complications but nevertheless, even minor complications increase the procedural trauma and may affect outcome in vulnerable, high risk patients. The incidence of stroke, acute renal failure and myocardial infarction were similar to those presented in previous studies and without differences between the groups (5, 17).
Procedural time, ICU stay and the time on ventilator decreased over time in the TAVI group and the differences are shown in the comparison between the first 25 and the last 20 patients. This is most likely due to the learning curve of a new procedure and also to the fact that hospital guidelines stated that TAVI patients should be treated as SAVR patients postoperatively at the introduction of the TAVI procedure.
Echocardiographic findings showed lower mean aortic pressure gradient and lower maximum transvalvular velocity in the TAVI group. The TAVI patients had lower BSA compared to the SAVR group but larger prostheses could be used at the TAVI procedure. Although the native aortic valve and annulus calcification is not excised at the TAVI procedure, the exclusion and compression of it leaves enough space for the prosthesis (21) . The space occupied by the sewing ring on the prostheses used at SAVR is larger than the limitation provided by the calcification left in the annulus at TAVI.
No paravalvular regurgitation was seen in the SAVR group. However, paravalvular regurgitation was detected in a majority of the TAVI patients but seemed to be of little hemodynamic importance at in-hospital follow up. However, recent data reveals an association between late mortality and even mild paravalvular regurgitation after TAVI (22) .
Paravalvular leakage seems to be related to the remaining annular calcification and the TAVI prostheses, even if the frequency of it may be reduced by oversizing of the prosthesis. The impact of paravalvular regurgitation on survival must be taken in account when TAVI is considered for patients with more than short expected lifetime. Hemolysis is a well-known complication of prosthetic heart valve replacement and paravalvular regurgitation may lead to increased hemolysis. Factors like blood turbulence and high-velocity shear forces are of special importance (23) . The different characteristics of how the aortic valve prostheses' are mounted in relation to clinical evident hemolytic complications need further exploration.
Scoring systems like the logEuroSCORE and the STS score are well established to predict mortality after cardiac surgery. The TAVI approach for treatment of aortic valve stenosis is less invasive and less traumatic and therefore regarded as a good option for patients with high surgical risk score. Nevertheless, the existing scoring systems may not capture all variables relevant in the choice of treatment for aortic valve stenosis. Obviously other factors have a strong influence on patient selection for TAVI in clinical practice (24) . The patients' opinion is one of these and it is dependent on available information in general and on information provided by responsible physician. Patient selection is crucial for outcome and the specific risk factors for mortality and morbidity after TAVI have to be further clarified (25) . It can not be assumed to be the same as for SAVR. It also remains to establish whether different risk evaluation system for cardiac surgery patients is appropriate for TAVI patients as well.
In conclusion, TAVI offers a safe short-term treatment with excellent good hemodynamic results in selected patients with high-risk for SAVR. Besides high logEuroSCORE, other factors influence the choice of therapy. In order to offer our patients the best treatment for aortic stenosis, comparisons between TAVI and SAVR regarding short and long term outcome and risk factors must continuously proceed. In addition, the selection criteria for TAVI need to be refined and evaluated. The issue of paravalvular leakage and valve durability need to be addressed and may influence the patient selection. 
